$291 Million is the total value of DAFNA Capital Management LLC's 81 reported holdings in Q4 2019. The portfolio turnover from Q3 2019 to Q4 2019 was 0.0% .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| STXS | STEREOTAXIS INC | $72,370,000 | +50.7% | 13,680,554 | 0.0% | 24.84% | +37.6% | |
| ATRC | ATRICURE INC | $10,362,000 | +30.4% | 318,729 | 0.0% | 3.56% | +19.0% | |
| BPMC | BLUEPRINT MEDICINES CORP | $9,871,000 | +9.0% | 123,218 | 0.0% | 3.39% | -0.5% | |
| FATE | FATE THERAPEUTICS INC | $9,198,000 | +26.0% | 470,000 | 0.0% | 3.16% | +15.0% | |
| SAGE | SAGE THERAPEUTICS INC | $9,010,000 | -48.5% | 124,806 | 0.0% | 3.09% | -53.0% | |
| DXCM | DEXCOM INC | $7,949,000 | +46.6% | 36,338 | 0.0% | 2.73% | +33.8% | |
| IBB | ISHARES TR NASDAQ BIOTECHetf | $7,821,000 | +21.1% | 64,900 | 0.0% | 2.68% | +10.5% | |
| LMNX | LUMINEX CORP | $4,727,000 | +12.2% | 204,091 | 0.0% | 1.62% | +2.4% | |
| CYTK | CYTOKINETICS INC | $4,443,000 | -6.8% | 418,727 | 0.0% | 1.52% | -14.9% | |
| RADIUS HEALTH INCnote 3.000% 9/0 | $3,395,000 | -7.4% | 4,000,000 | 0.0% | 1.16% | -15.5% | ||
| ACHN | ACHILLION PHARMACEUTICALS | $2,646,000 | +67.5% | 438,884 | 0.0% | 0.91% | +52.9% | |
| DRNA | DICERNA PHARMACEUTICALS INC | $2,606,000 | +53.4% | 118,314 | 0.0% | 0.90% | +40.1% | |
| ALEC | ALECTOR INC | $2,498,000 | +19.5% | 145,000 | 0.0% | 0.86% | +9.0% | |
| CSII | CARDIOVASCULAR SYSTEMS INC | $2,245,000 | +2.3% | 46,200 | 0.0% | 0.77% | -6.7% | |
| BLUE | BLUEBIRD BIO INC | $2,238,000 | -4.4% | 25,500 | 0.0% | 0.77% | -12.7% | |
| PHAS | PHASEBIO PHARMACEUTICALS INC | $2,203,000 | +46.6% | 360,542 | 0.0% | 0.76% | +33.8% | |
| ARAY | ACCURAY INC | $1,902,000 | +1.8% | 674,300 | 0.0% | 0.65% | -7.1% | |
| ARCT | ARCTURUS THERAPEUTICS HLDG I | $1,890,000 | +5.8% | 173,914 | 0.0% | 0.65% | -3.4% | |
| VKTX | VIKING THERAPEUTICS INC | $1,678,000 | +16.6% | 209,200 | 0.0% | 0.58% | +6.5% | |
| AGTC | APPLIED GENETIC TECHNOL CORP | $1,624,000 | +8.7% | 359,190 | 0.0% | 0.56% | -0.9% | |
| CRBP | CORBUS PHARMACEUTICALS HLDGS | $1,623,000 | +12.1% | 297,300 | 0.0% | 0.56% | +2.2% | |
| INGN | INOGEN INC | $1,572,000 | +42.6% | 23,000 | 0.0% | 0.54% | +30.4% | |
| NTUS | NATUS MEDICAL INC | $1,415,000 | +3.6% | 42,900 | 0.0% | 0.49% | -5.4% | |
| JNJ | JOHNSON AND JOHNSON | $1,371,000 | +12.7% | 9,400 | 0.0% | 0.47% | +3.1% | |
| AUTL | AUTOLUS THERAPEUTICS PLCspon ads | $1,320,000 | +6.3% | 100,000 | 0.0% | 0.45% | -3.0% | |
| PRVL | PREVAIL THERAPEUTICS INC | $1,187,000 | +28.9% | 75,000 | 0.0% | 0.41% | +17.6% | |
| GNCA | GENOCEA BIOSCIENCES INC | $1,123,000 | -28.6% | 542,564 | 0.0% | 0.38% | -35.0% | |
| CTMX | CYTOMX THERAPEUTICS INC | $831,000 | +12.6% | 100,000 | 0.0% | 0.28% | +2.5% | |
| INSM | INSMED INC | $716,000 | +35.3% | 30,000 | 0.0% | 0.25% | +23.6% | |
| DEXCOM INCnote 0.750% 5/1 | $556,000 | +40.1% | 250,000 | 0.0% | 0.19% | +28.2% | ||
| MASI | MASIMO CORPORATION | $474,000 | +6.3% | 3,000 | 0.0% | 0.16% | -3.0% | |
| GRTS | GRITSTONE ONCOLOGY INC | $449,000 | +3.9% | 50,000 | 0.0% | 0.15% | -4.9% | |
| RDUS | RADIUS HEALTH INC | $444,000 | -21.7% | 22,000 | 0.0% | 0.15% | -28.6% | |
| KALV | KALVISTA PHARMACEUTICALS INC | $440,000 | +53.3% | 24,725 | 0.0% | 0.15% | +39.8% | |
| STRO | SUTRO BIOPHARMA INC | $440,000 | +20.9% | 40,000 | 0.0% | 0.15% | +10.2% | |
| ZFGN | ZAFGEN INC | $339,000 | +50.0% | 305,500 | 0.0% | 0.12% | +36.5% | |
| RIGL | RIGEL PHARMACEUTICALS INC | $337,000 | +14.2% | 157,700 | 0.0% | 0.12% | +4.5% | |
| ADXS | ADVAXIS INC | $300,000 | +222.6% | 350,000 | 0.0% | 0.10% | +194.3% | |
| LCTX | LINEAGE CELL THERAPEUTICS IN | $85,000 | -8.6% | 95,000 | 0.0% | 0.03% | -17.1% |
Other managers
Other managers that, in addition to the filing manager(s), that filed the EDGAR filing(s):
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2020-02-14
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| STEREOTAXIS INC | 42 | Q3 2023 | 27.6% |
| ATRICURE INC | 42 | Q3 2023 | 11.4% |
| MASIMO CORPORATION | 42 | Q3 2023 | 1.8% |
| ASCENDIS PHARMA A S SPONSORED | 34 | Q3 2023 | 4.5% |
| AERIE PHARMACEUTICALS INC | 33 | Q3 2022 | 4.2% |
| GALAPAGOS NV-SPON ADR | 33 | Q3 2023 | 3.8% |
| XENON PHARMACEUTICALS INC | 33 | Q3 2023 | 3.6% |
| NEUROCRINE BIOSCIENCES INC | 32 | Q3 2023 | 2.9% |
| JOHNSON AND JOHNSON | 32 | Q1 2021 | 1.2% |
| ISHARES TR NASDQ BIOTECH | 30 | Q3 2023 | 4.0% |
View DAFNA Capital Management LLC's complete holdings history.
Latest significant ownerships (13-D/G)
| Filed | Shares | Percentage | |
|---|---|---|---|
| Stereotaxis, Inc. | March 08, 2018 | 13,680,554 | 23.4% |
| SUNESIS PHARMACEUTICALS INC | February 14, 2018 | 983,000 | 2.9% |
| SUNESIS PHARMACEUTICALS INC | February 14, 2017 | 1,133,583 | 5.4% |
| WINDTREE THERAPEUTICS INC /DE/ | February 14, 2017 | 208,333 | 2.4% |
| ANAVEX LIFE SCIENCES CORP.Sold out | February 16, 2016 | 0 | 0.0% |
| DISCOVERY LABORATORIES INC /DE/ | February 16, 2016 | 10,658,699 | 9.2% |
| PRECISION OPTICS CORPORATION, INC. | February 13, 2015 | 311,537 | 5.0% |
| TearLab Corp | February 14, 2013 | 939,239 | 3.2% |
| VIKING SYSTEMS INC | February 14, 2012 | 3,781,468 | 5.2% |
View DAFNA Capital Management LLC's complete significant-ownership history.
Latest filings
| Type | Filed |
|---|---|
| 13F-HR | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
| SC 13G | 2024-02-14 |
| 13F-HR | 2023-11-14 |
| 13F-HR | 2023-08-14 |
| 13F-HR | 2023-05-15 |
| SC 13G/A | 2023-02-14 |
| 13F-HR | 2023-02-14 |
| 13F-HR | 2022-11-14 |
| 13F-HR | 2022-08-15 |
View DAFNA Capital Management LLC's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.